HC Wainwright & Co. reiterates Buy rating on Celldex Therapeutics, $64 price target
HC Wainwright & Co. maintained a Buy rating on Celldex Therapeutics with a $64 price target, implying a 98.9% upside from the Oct 1 close of $32.18. The company's pipeline focuses on severe inflammatory and autoimmune diseases, and surveys indicate positive physician sentiment despite safety concerns.
How this was made
The 30-second read
Why it matters
The reiterated Buy rating and $64 target suggest analysts see significant upside, but no new trial data or regulatory events were disclosed.
Market read
The article offers a fresh analyst opinion that could modestly influence CLDX's share price, but lacks substantive new corporate events.
What to watch
No new clinical data released; the rating is based on pipeline expectations.
Background
Celldex Therapeutics (CLDX) is a biotech developing monoclonal and bispecific antibodies for inflammatory and autoimmune diseases.
Ticker impact
HC Wainwright reiterated a Buy rating on Celldex Therapeutics with a new $64 price target, implying ~99% upside from the recent close.
potential upward pressure as investors price in the higher target
The rating change is a fresh analyst opinion that could attract buying interest.
Market effects
May boost sentiment toward biotech stocks targeting inflammatory diseases.
Limited to U.S. biotech investors.
Low, confined to Celldex and its immediate peers.
Counterpoint
Investors may view the target as overly optimistic given safety concerns.
Key entities
- Analyst FirmHC Wainwright & Co.
Equity research firm providing the rating and price target.
- CompanyCelldex Therapeutics
Biopharmaceutical company developing antibody therapies.
